Navigation Links
A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List

In an otherwise bleak healthcare scenario has emerged a heartening development.The World Health Organisation (WHO) has designated Paromomycin IM injection manufactured by the US based Institute for OneWorld Health, a non-profit drug firm, for inclusion in its Model List for Essential Medicines.

Paromomycin IM Injection is a cost-effective treatment for visceral leishmaniasis (VL), the worlds second most deadly parasitic disease after malaria.

It is a systemic infection caused by various species of Leishmania parasites. The infection is transmitted by sandflies and causes chronic fever, weight loss, anemia and spleen and liver and anemia. With approximately 500,000 new cases occurring annually worldwide, visceral leishmaniasis, also known as kala azar, primarily afflicts the rural poor.

Left untreated, VL is nearly always fatal. VL currently occurs in 62 countries, primarily in the developing world. Of the approximately 500,000 new cases of VL occurring annually, 90% are found in just five countries: India, Bangladesh, Nepal, Sudan and Brazil.

The Indian subcontinent carries 70% of all estimated new VL cases per year worldwide, with India alone is burdened with 50% percent of all new cases. The most affected state in India is Bihar, but VL is also endemic in the states of Jharkand, West Bengal, and Uttar Pradesh.

Paromomycin, an off-patent aminoglycoside antibiotic, is an established drug with an extensive and well-characterized safety profile. Paromomycin IM Injection is now available for the first time as a new treatment of VL as a once-a-day injection for 21 days. The cost of Paromomycin IM Injection is significantly lower than other currently approved VL therapies.

The WHO List of Essential Medicines provides a model for countries to select medicines addressing public health priorities. Medicines are selected by the WHOs Expert Committee on the Selection and Use of Essential Med
'"/>




Page: 1 2 3

Related medicine news :

1. Firms Told To Employ Those With Aspergers Syndrome
2. Drug Firms To Produce Single Pill AIDS Treatment
3. 12 Chinese Firms Appeal Against Court Ruling On Viagra
4. Drug Firms Meet Annan, Pledge on AIDS Medicines
5. Drug Firms Competing to Produce Cheap and Effective bird flu vaccine
6. US, India Firms Develop New Cure for Black Fever
7. Chemical Firms are Secretly Paying Scientists
8. Supreme Court Seeks Replies From Cola Firms
9. Nexus Between Psychiatrists and Drug Firms Dangerous, Say Critics
10. Injection supports Heart Devices
11. Abstinence From Alcohol With The Help Of An Injection
Post Your Comments:
(Date:9/5/2008)...heoretical ,anti-cloak, could bring objects out of...ews) -- Just in case someone develops a cloak of i... know how to uncloak the objects it hides. , Ac...certain materials underneath an invisibility cloak..., Researchers at Shanghai Jiao Tong University i...
(Date:9/5/2008).... 5 /PRNewswire/ -- Arthrosurface, Inc.,( http://w...sive joint,resurfacing systems, announced that it ...ts pivotal investigation for its line of focal kne... are no outstanding safety,concerns" with the devi...ce has been evaluating the safety and efficacy of ...
(Date:9/5/2008)...ept. 5 /PRNewswire/ -- Tonight is a momentous,occa...tainment industry,executives, celebrities and prom...acy join forces to Stand Up to Cancer. This collab...p.m. to 9:00 p.m. ET on the three,networks -- ABC,...o elevate,the discussion about cancer and the need...
(Date:9/5/2008)...ewswire/ -- EthicAd, a nonprofit organization,devo...ucation, announces,the launch of a new FDA Web sit...tand direct-to-consumer (DTC) advertising of presc...scription Drug Advertising," is,hosted by the FDA,...developed by the FDA in partnership with EthicAd. ...
Breaking Medicine News(10 mins):Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2
...ple with heart disease to travel by air? For the s...idence on // issues involving air travel for heart... security devices on implantable automatic defibri...reening, and the potential for in-flight deep vein...
...focused on depression in elderly people living in ...s or nursing homes found that // depression and it...many elderly people . The study, involved 250 part...At the start of the study, researchers determined ...
...ey may have found a way to diagnose melancholic de...hem to observe // levels of certain substances in...m of depression marked by insomnia, loss of appeti... study show low levels of the inhibitory transmitt...
...roup of diseases that affect the lungs, including ...rized by permanent // lung damage and irreversible...d, the airways become inflamed, causing airflow ob...e to the lungs is not thought to be permanent. Plu...
Other Medicine News:
(Date:9/5/2008)...W.Va., Sept. 5 /PRNewswire-USNewswire/ -- A team o...n that U.S. immigrants from,India and Pakistan tak...ng,their risks of prostate cancer among male immig...ancer and prostate cancer develop due to many reas...a major role in these cancers,",said Jame Abraham,...
(Date:9/4/2008)...alif., Sept. 4 /- BioForm M... the pivotal clinical study of,Polidocanol, conduc...sche,Fabrik KREUSSLER & Co. GmbH (Kreussler), succ...en submitted to FDA as part of a New Drug Applicat..., named the EASI (Efficacy and safety of,Aethoxysk...
(Date:9/4/2008)...Ala., Sept. 4 /- Southern Research In...es of Health (NIH) has selected,the organization t...ies,Probe Production Center Network (MLPCN). The M...t of the Molecular Libraries Program which is,desi...nowledge of the human,genome and validate future t...
(Date:9/4/2008)...demonstrates potent antiviral activity and favorab... CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstCall/... a biopharmaceutical company engaged,in the discov...human viral,and other infectious diseases, today a...t study evaluating IDX899, a non-nucleoside revers...
Breaking Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Six Finalists Announced for 2008 Insight Award for Customer Advocacy in Financial Services 14164 1ESFs European ice core project EPICA receives prestigious Descartes Prize 2477 1ESFs European ice core project EPICA receives prestigious Descartes Prize 2477 2ESFs European ice core project EPICA receives prestigious Descartes Prize 2477 3Gene Hunters Fine Tune Marker for Common Obesity Gene 1509 1Gene Hunters Fine Tune Marker for Common Obesity Gene 1509 2Gene Hunters Fine Tune Marker for Common Obesity Gene 1509 3Caring com Joins Entrepreneurs Foundation as 200th Member 14153 1Caring com Joins Entrepreneurs Foundation as 200th Member 14153 2
...une 14, 2007 /PRNewswire-FirstCall/ Haemacure,Corp...cs company,today announced the preliminary findin...scards. , Preliminary findings confirm the presenc...tions in significant worldwide,markets, including ...hese findings take on a strategic significance for...
...(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. ...omise to,revolutionize pulmonary drug delivery. Th...d air to deliver medications deep into the,pulmona... delivery,systems because it rapidly administers a...viously unrealized efficiencies. The,delivery tech...
Other Medicine Technology:Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 2Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 3Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 4Next Safety, Inc.'s Innovative Drug Delivery System Will Replace,Cigarettes and Significantly Advance Pulmonary Medication Delivery 2
100cc silicone evacuator with hubless flat drain and trocar
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag.
Silicone Flat Hubless Drains
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe.
Medicine Products: